The Company sells the Product principally to a limited number of customers consisting of telemedicine and online pharmacies, that in turn resell the Product to consumers.

Revenue for the three months ended March 31, 2023 and March 31, 2022 consisted of the following (in thousands):


	For the three months ended March 31,
	2023		2022
Roman Health Pharmacy LLC	$	1,015	$	6,499
GoGoMeds		661		1,015
CMS		77		—
Total	$	1,753	$	7,514

During the three months ended March 31, 2023 and March 31, 2022, the Company recognized $1.0 million and $6.5 million, respectively, of product revenue, net, in the accompanying condensed consolidated statements of operations with respect to Roman Health Pharmacy LLC, or Ro. At March 31, 2023 and December 31, 2022, the Company recorded a deferred income balance of $24.7 million and $25.9 million, respectively, in the accompanying condensed consolidated balance sheets representing customer prepayment available to be used for future Product purchases with respect to Ro.

During three months ended March 31, 2023 and March 31, 2022, the Company recognized $0.7 million and $1.0 million, respectively, of product revenue, net, in the accompanying condensed consolidated statements of operations with respect to Specialty Medical

Drugstore, LLC, d/b/a/ GoGoMeds, or GGM. At March 31, 2023 and December 31, 2022, the Company recorded an accounts receivable balance of $1.3 million and $1.1 million, respectively, prior to reserves and allowances, in the accompanying condensed consolidated balance sheets with respect to GGM.

During the three months ended March 31, 2023 and March 31, 2022, the Company recognized $0.1 million and $0.0 million, respectively, of product revenue, net, in the accompanying condensed consolidated statements of operations with respect to CMS.

Reserves and Allowances

The following table summarizes the activity in the product revenue reserve and allowances during the three months ended March 31, 2023 and March 31, 2022 (in thousands):


	2023			2022
Balance at January 1,	$	23		$	82
Provision related to product sales		210			574
Credits and payments made		(226	)		(418	)
Balance at March 31,	$	7		$	238

At March 31, 2023 and 2022, product related reserve and allowances comprised solely contractual adjustments owed to the Company’s telehealth and online pharmacy partners, which were netted to accounts receivable in the Company’s condensed consolidated balance sheets for the year. Through March 31, 2023, there had been no product related reserves or allowances owed to other parties, including the federal and state governments or their agencies.